The classic psychedelic DOI induces a persistent desynchronized state in medial prefrontal cortex
This pre-print (2023) rodent study found that DOI caused changes in brain activity (specifically the mPFC) that differed from normal patterns. During rest, when brain activity is usually synchronized, the drug causes a decrease in synchronization and an increase in gamma activity.
Authors
- Olson, R.
- Bartlett, L.
- Sonneborn, A.
Published
Abstract
Administration or consumption of classic psychedelics (CPs) leads to profound changes in experience which are often described as highly novel and meaningful. They have shown substantial promise in treating depressive symptoms and may be therapeutic in other situations. Although research suggests that the therapeutic response is correlated with the intensity of the experience, the neural circuit basis for the alterations in experience caused by CPs requires further study. The medial prefrontal cortex (mPFC), where CPs have been shown to induce rapid, 5-HT2A receptor-dependent structural and neurophysiological changes, is believed to be a key site of action. To investigate the acute neural circuit changes induced by CPs, we recorded single neurons and local field potentials in the mPFC of freely behaving mice after administration of the 5-HT2A/2C receptor-selective CP, 2,5-Dimethoxy-4-iodoamphetamine (DOI). We segregated recordings into active and rest periods in order to examine cortical activity during desynchronized (active) and synchronized (rest) states. We found that DOI induced a robust decrease in low frequency power and decoupled rhythmic activity from neural population dynamics when animals were at rest, attenuating the usual synchronization that occurs during less active behavioral states. DOI also increased broadband gamma power and suppressed activity in fast-spiking neurons in both active and rest periods. Together, these results show that the CP DOI induces persistent desynchronization in mPFC, including during rest when mPFC typically exhibits more synchronized activity. This shift in cortical dynamics may in part underlie the longer-lasting effects of CPs on plasticity, and may be critical to their therapeutic properties.
Research Summary of 'The classic psychedelic DOI induces a persistent desynchronized state in medial prefrontal cortex'
Introduction
Classic psychedelics (CPs) produce profound alterations in subjective experience and have re-emerged as candidate therapeutics for treatment-resistant depression and other psychiatric conditions. Their principal psychoactive action is mediated by Gq-coupled 5-HT2A receptors (5-HT2ARs), which are highly expressed in medial prefrontal cortex (mPFC). Previous work links CPs to rapid 5-HT2AR-dependent structural and functional plasticity, but the acute circuit-level neurophysiological changes that precede plasticity are less well characterised, particularly in vivo during freely behaving states. Olson and colleagues set out to characterise how a prototypical 5-HT2A/2C-selective CP, 2,5-dimethoxy-4-iodoamphetamine (DOI), alters mPFC network dynamics in awake, freely moving mice. They tested the hypothesis that DOI produces behavioural state-dependent shifts in cortical synchrony by recording single-unit spiking and local field potentials (LFPs) from ventral mPFC before and after systemic DOI, and comparing activity during segregated active and rest periods.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Topics
- APA Citation
Olson, R. J., Bartlett, L., Sonneborn, A., Bretton-Granatoor, Z., Firdous, A., Harris, A. Z., & Abbas, A. I. (2023). The classic psychedelic DOI induces a persistent desynchronized state in medial prefrontal cortex. https://doi.org/10.1101/2023.02.26.529963
References (12)
Papers cited by this study that are also in Blossom
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Romeo, B., Hermand, M., Pétillion, A. et al. · Journal of Psychiatric Research (2021)
Quednow, B. B., Kometer, M., Geyer, M. A. et al. · Neuropsychopharmacology (2011)
Becker, A. M., Klaiber, A., Holze, F. et al. · International Journal of Neuropsychopharmacology (2022)
Torregrossa, M. M., Lu, J., Lukasiewicz, K. et al. · Frontiers in Molecular Neuroscience (2021)
Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)
Shao, L-X,, Liao, C., Gregg, I. et al. · Neuron (2021)
Riba, J., Valle, M., Urbano, G. et al. · Journal of Pharmacology and Experimental Therapeutics (2003)
Show all 12 referencesShow fewer
Kometer, M., Pokorny, T., Seifritz, E. et al. · Psychopharmacology (2015)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.